Patents
Literature
2896 results about "Binding protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A binding protein is any protein that acts as an agent to bind two or more molecules together. Examples include: DNA-binding protein Single-strand binding protein Telomere-binding protein RNA-binding protein Poly-binding protein Nuclear cap-binding protein complex CREB-binding protein Calcium-binding protein Calcium-binding protein 1 S100 calcium-binding protein A1 TATA-binding protein Actin-binding protein Penicillin binding proteins Retinol binding protein Retinol binding protein 4 EP300 Binding immunoglobulin protein Odorant binding protein Lipopolysaccharide-binding protein C4b-binding protein Rap GTP-binding protein Calmodulin-binding proteins Iron-binding proteins Thyroxine-binding proteins Folate-binding protein Sterol regulatory element-binding protein GTP-binding protein Retinaldehyde-binding protein 1 Ccaat-enhancer-binding proteins Androgen-binding protein Maltose-binding protein Phosphatidylethanolamine binding protein 1 Syntaxin binding protein 3 Insulin-like growth factor-binding protein Methyl-CpG-binding domain protein 2 Growth hormone-binding protein Vitamin D-binding protein Syntaxin binding protein 2 Oxysterol-binding protein E3 binding protein
Methods of using anti-SP17 immunotherapeutics
ActiveUS12319747B2Microbiological testing/measurementBiological material analysisSperm proteinTherapeutic antibody
This disclosure describes proteins that specifically bind human sperm protein 17 (Sp17) with nanomolar affinity and high specificity. These proteins include a recombinant human anti-Sp17 IgG that is suitable for use as a therapeutic antibody to treat cancers that ectopically express Sp17. Other Sp17-binding proteins are described including antibody fragments, antibody conjugates, and fusion proteins.
Owner:MEDICOVESTOR INC
TL1a binding antibodies and methods of use
PCT designated stage expiredWO2025038473A1AntipyreticAnalgesicsAntiendomysial antibodiesAntigen binding
Owner:PARAGON THERAPEUTICS INC
α4β7 integrin binding proteins and methods of use
PCT designated stage expiredWO2025038708A1AntipyreticAnalgesicsAntiendomysial antibodiesCell biology
Owner:PARAGON THERAPEUTICS INC
Kit and detection method for detecting tomato brown crinkled fruit virus based on enzyme-mediated dual-amplification nucleic acid amplification
PendingCN120210426AMicrobiological testing/measurementDNA/RNA fragmentationEnzyme systemSingle strand
The invention discloses a kit for detecting tomato brown crinkled fruit virus based on enzyme-mediated dual-amplification nucleic acid amplification and a detection method. The detection system comprises a primer pair DNA (deoxyribonucleic acid) upstream primer (F5) and a DNA downstream primer (R6) for amplifying the tomato brown crinkled fruit virus movement protein gene, a probe (RNA primer (RNA1)) for detecting the MP gene, a nucleic acid amplification group enzyme system (recombinase, single-chain binding protein, polymerase and ATP (adenosine triphosphate) energy regeneration enzyme), a signal amplification group enzyme system (positioning enzyme and cutting enzyme), activating enzyme NTP, a buffer solution and RNase-free Water. The system composed of the freeze-drying protective agent is prepared into the pre-subpackaged freeze-dried balls. The kit disclosed by the invention can realize DNA detection of aM concentration, and besides rapid qualitative detection of the tomato brown crinkled fruit virus, early screening of the tomato brown crinkled fruit virus can also be realized due to high detection sensitivity.
Owner:SUZHOU JINGRUI BIOTECHNOLOGY CO LTD +2
Anti-p-Tau217 protein monoclonal antibody as well as preparation method and application thereof
The invention provides a monoclonal antibody of a p-Tau217 protein and an application of the monoclonal antibody. In particular, the present invention provides an antibody or an antigen binding fragment thereof targeting a p-Tau217 protein. The antibody provided by the invention can specifically recognize and bind the p-Tau217 protein, does not recognize p-Tau181 and non-phosphorylated Tau protein, and can be used for preparing a detection preparation or a kit for diagnosing diseases related to the p-Tau217 protein, such as Alzheimer's disease.
Owner:SHANGHAI BIOGERM MEDICAL TECH CO LTD +1
Test strip for rapidly detecting methicillin-resistant staphylococcus aureus and application of test strip
The invention provides a test strip for rapidly detecting methicillin-resistant staphylococcus aureus and application of the test strip, and belongs to the technical field of biochemical detection. The test strip comprises a bottom plate, a sample pad, a combination pad, a detection pad and a water absorption pad, the two ends of the detection pad are in lap joint with the combination pad and the water absorption pad respectively, the detection pad is located on the lower portion, the sample pad is in lap joint with the combination pad, and the combination pad is located on the lower portion; a detection line and a quality control line are arranged on the detection pad, the detection line is arranged on one side close to the combination pad, and the quality control line is arranged on one side close to the water absorption pad; the detection pad is coated with a MoS2 nanosheet, the combination pad is coated with a penicillin binding protein 2a polyclonal antibody labeled by horse radish peroxidase, and the detection line is coated with a penicillin binding protein 2a monoclonal antibody; the quality control line is coated with goat anti-rabbit IgG (immunoglobulin G). The kit is high in sensitivity and wide in linear range, has good specificity, repeatability and stability, and can effectively detect MRSA in a clinical sample.
Owner:CHONGQING NO 3 PEOPLES HOSPITAL
A nucleic acid aptamer binding to CD117 protein and its application
PendingCN119752914AOrganic active ingredientsCell receptors/surface-antigens/surface-determinantsAptamerAbnormal expression
The present invention discloses a nucleic acid aptamer binding to CD117 protein and its application, wherein the nucleic acid aptamer has a nucleotide sequence that has at least 60% homology with any one of SEQ ID NO.1 to SEQ ID NO.2 and binds to CD117 protein. The nucleic acid aptamer of the present invention has a small molecular weight, stable structure and chemical properties, is easy to store and label, is easy to modify, and can be artificially synthesized in a short period of time. The nucleic acid aptamer obtained by the present invention can be used for CD117 protein detection, purification or imaging, and can also be used to prepare drugs for diagnosis or treatment of abnormal expression of CD117 protein, such as purification to obtain high-sensitivity and high-specificity detection of CD117 protein, and has broad application prospects.
Owner:HANGZHOU INSTITUTE OF MEDICAL SCIENCES CHINESE ACADEMY OF SCIENCES
Base editing system based on TraC effect protein and application thereof
The invention belongs to the field of gene engineering, and relates to a DNA binding protein based on TraC effect protein, a fusion protein with a cytosine / adenine base editing function, an editing system and nucleic acid molecules or constructs for encoding the DNA binding protein and the fusion protein. The invention also relates to complexes and kits for gene editing comprising the fusion proteins of the invention or the nucleic acid molecules encoding them. The base editing tool disclosed by the invention can realize efficient, accurate and safe base editing in cells of various eukaryotes such as animals and plants. The unique characteristics of the base editing tool enrich the types of existing base editing tools, and the base editing tool has wide application prospects.
Owner:BEIJING QI BIODESIGN BIOTECHNOLOGY CO LTD
Protein binder search
A specification of a binding target protein is received. A machine learning model is used to predict a plurality of candidates for a property of a selected amino acid position of a binder protein to bind to the binding target protein. For each selected property candidate of the plurality of property candidates, the selected property candidate is used as a model input to predict properties for one or more other amino acid positions into a corresponding candidate set of properties. The corresponding candidate sets are evaluated using a binding quality evaluation. Based on the evaluation, one of the plurality of property candidates is selected as a determined result property of the selected amino acid position. The determined result property is used as a model input to predict a plurality of candidates for a property of a different selected amino acid position included in the binder protein.
Owner:CHAN ZUCKERBERG BIOHUB INC
DHODH polypeptide degradation agent and application thereof in preparation of medicine for preventing and / or treating DHODH-mediated diseases
ActiveCN120192429APolypeptide with localisation/targeting motifFusion with degradation motifDiseaseUbiquitin ligase
The invention provides a DHODH polypeptide degradation agent and application of the DHODH polypeptide degradation agent in preparation of drugs for preventing and / or treating DHODH-mediated diseases, and belongs to the technical field of biological medicines. The invention provides a DHODH polypeptide degradation agent. The DHODH polypeptide degradation agent comprises a cell-penetrating peptide, a DHODH binding peptide, a linker and an E3 ubiquitin ligase VHL binding peptide which are sequentially connected from an N terminal to a C terminal. The DHODH polypeptide degradation agent provided by the invention can be efficiently combined with DHODH protein, and has a good anti-tumor effect on the cellular level and the animal level. The compound has a good application prospect in preparation of drugs for preventing and treating DHODH-mediated diseases, overcomes the defects that existing drugs for treating DHODH-related diseases are single in variety and insufficient in curative effect, and has important significance.
Owner:EAST CHINA UNIV OF SCI & TECH +1
Application of rice BRW1 gene in regulation and control of grain weight character
ActiveCN120041469AClimate change adaptationMicrobiological testing/measurementBiotechnologyGrain weight
The invention belongs to the field of gene engineering, and relates to a rice BRW1 gene and application thereof. The cDNA (complementary deoxyribonucleic acid) sequence of the rice BRW1 gene is shown as SEQ ID NO.1, and the amino acid sequence of the RNA binding protein coded by the rice BRW1 gene is shown as SEQ ID NO.2. The invention discloses the rice RNA binding protein gene BRW1 and the protein coded by the rice RNA binding protein gene BRW1. The rice BRW1 gene controls the grain weight of grains, the thousand grain weight of a knockout mutant of the gene is remarkably increased, and meanwhile the grain length and the grain width are increased. By mutating the BRW1 gene in the invention, the grain weight of rice grains can be increased, which indicates that the genetic improvement of the grain weight and grain shape of rice is facilitated by using the gene.
Owner:NANJING AGRICULTURAL UNIVERSITY
Albumin binding proteins and methods of use
Owner:PARAGON THERAPEUTICS INC
Nucleic acid aptamer combined with TIDG6 protein as well as application and screening method of nucleic acid aptamer
PendingCN119685320ARadioactive preparation carriersPharmaceutical non-active ingredientsAptamerRNA Sequence
The invention relates to the technical field of biology, in particular to a nucleic acid aptamer combined with TIDG6 protein, application and a screening method of the nucleic acid aptamer, and the nucleic acid aptamer has a nucleotide sequence as shown in SEQ ID NO.1; or a nucleotide sequence which has at least 30% homology with SEQ ID NO.1 and is combined with TIDG6 protein; the nucleic acid aptamer is an RNA sequence transcribed by a nucleotide sequence as shown in SEQ ID NO.1, or an RNA sequence transcribed by a nucleotide sequence as shown in SEQ ID NO.1. The nucleic acid aptamer is small in molecular weight, stable in chemical property, easy to store and mark, capable of being combined with TIDG6 protein with high affinity, very good in specificity, capable of being used in the aspects of detection, diagnosis, imaging, treatment and the like and wide in application prospect.
Owner:ZHEJIANG UNIV OF TECH +1
Dissociation agent and kit
PCT designated stage expiredWO2025087337A1Biological testingFluorescence/phosphorescenceProteasePathology
Disclosed in the present invention are a dissociation agent and a detection kit for thyroid function detection. The dissociation agent comprises a protease and a reducing agent, and can effectively dissociate the bound forms of T3 and T4 in serum from binding proteins to form a free state. The dissociation agent and kit of the present invention are used for fluorescent immunochromatography detection, so that signal interference can be effectively reduced, and the sensitivity and accuracy of the detection can be improved.
Owner:LEADWAY HK
Composition for detecting NAD < + > and application thereof
The invention specifically discloses a composition for detecting NAD < + > and application thereof, and relates to the technical field of biological detection. According to the composition for detecting NAD < + >, the composition comprises an NAD < + > binding protein fragment A connected with an Fc tag, an NAD < + > binding protein fragment B and a connecting peptide, the detection result is accurate and reliable, and meanwhile the technical difficulty, uncertainty and high cost faced by antibody screening in a traditional method are avoided.
Owner:HEFEI KNATURE BIO PHARM CO LTD
Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
ActiveUS12226424B2Organic chemistryPharmaceutical non-active ingredientsProtein targetChemical compound
The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), intermediates of formula (IV), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and / or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.
Owner:SHANGHAI TECH UNIV
Ligand discovery and gene delivery via retroviral surface display
ActiveUS20250147007A1Tumor rejection antigen precursorsAntibody mimetics/scaffoldsGene deliverySurface display
Disclosed herein are compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.
Owner:MASSACHUSETTS INST OF TECH
Diacylglycerol acyltransferase mutant and application thereof in synthesis of triacylglycerol by saccharomyces cerevisiae
The invention relates to a diacylglycerol acyltransferase mutant and application thereof in synthesis of triacylglycerol from saccharomyces cerevisiae, and belongs to the technical field of enzyme engineering. Diacylglycerol acyltransferase is a rate-limiting step of a synthetic route of saccharomyces cerevisiae triacylglycerol (TAG), and at present, a research on a DGA1 mutant for efficiently synthesizing TAG is lacked, and a research on the aspect of a DGA1 catalytic mechanism is also lacked. The DGA1 mutant capable of effectively improving TAG synthesis is obtained by screening in combination with a directed evolution technology, and a result shows that 282-site mutation of diacylglycerol acyltransferase can significantly increase the accumulation amount of TAG. Meanwhile, the catalytic mechanism of the DGA1 is preliminarily explored by combining protein structure prediction, molecular docking and molecular dynamics simulation, and a foundation is laid for deeply analyzing the catalytic mechanism of the DGA1. The recombinant saccharomyces cerevisiae is also constructed based on the mutant, so that the TAG synthesis is improved, and meanwhile, the relative proportion of C18: 1 in total fatty acids is remarkably increased.
Owner:JIANGNAN UNIV
Methods and compositions for prime editing nucleotide sequences
Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and / or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.
Owner:THE BROAD INST INC
Albumin binding proteins and methods of use
Owner:PARAGON THERAPEUTICS INC
Application of soybean nucleolus GTP binding protein gene GmNSN1 in soybean resistance to soybean mosaic virus disease
The invention discloses an application of a soybean nucleolus GTP binding protein gene GmNSN1 in soybean resistance to soybean mosaic virus diseases. The invention relates to an application of a soybean nucleolus GTP binding protein gene GmNSN1 as shown in SEQ ID NO.1 and SEQ ID NO.2 in genetic engineering modification of soybean mosaic virus resistance. The soybean nucleolus GTP binding protein gene GmNSN1 can negatively regulate and control the resistance of soybeans to diseased soybean mosaic virus diseases, and the antiviral response of the soybeans can be activated due to function deficiency of the soybean nucleolus GTP binding protein gene GmNSN1. The gene is knocked out through a CRISPR / Cas9 gene editing technology, so that the resistance of soybeans to the soybean mosaic virus disease can be remarkably improved.
Owner:NANJING AGRICULTURAL UNIVERSITY
Recombinant bacterium for overexpressing uranyl binding protein and application of recombinant bacterium
The invention relates to a recombinant bacterium for overexpressing uranyl binding protein and application of the recombinant bacterium, and belongs to the technical field of microorganisms. Bacterial outer membrane protein and uranyl binding protein are expressed in host bacteria, and the uranyl binding protein is anchored on an outer membrane of recombinant bacteria through the bacterial outer membrane protein, so that the uranyl binding protein anchored on the bacterial outer membrane can adsorb uranyl ions. Meanwhile, the invention finds that the expression quantity of the uranyl binding protein can be increased by performing fusion expression on the uranyl binding protein by using LPP-OMPA, so that the adsorption effect of uranyl ions is improved. The recombinant bacterium is prepared into a freeze-dried capsule product, and the freeze-dried capsule product can penetrate through a stomach barrier and is accurately delivered to intestinal tracts so as to realize uranyl ion adsorption.
Owner:LANZHOU UNIV
Biomarker for predicting curative effect of non-small cell lung cancer immunotherapy and application thereof
ActiveCN119757766AMaterial analysis by electric/magnetic meansBiological testingChromogranin ACancer research
The invention relates to a biomarker for predicting the curative effect of non-small cell lung cancer immunotherapy and application of the biomarker. The biomarker for predicting the curative effect of the non-small cell lung cancer immunotherapy, disclosed by the invention, comprises phosphoglycerate kinase 1 (PGK1), chromogranin A (CHGA), elastin (ELN), heterogeneous ribonucleoprotein H3 (HNRNPH3) and SERPINE1 mRNA binding protein 1 (SERBP1). The biomarkers for predicting the non-small cell lung cancer immunotherapy curative effect can be detected by adopting a mass spectrum method, and the non-small cell lung cancer immunotherapy curative effect of a patient is judged by the markers.
Owner:SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & CONTROL INSTITUTE)
Application of ACBD3 inhibitor in preparation of medicine for treating lung cancer and gRNA for inhibiting ACBD3 gene expression
PendingCN119770658AOrganic active ingredientsAntibacterial agentsCancer cellTreatment of lung cancer
The invention relates to application of an ACBD3 inhibitor in preparation of a medicine for treating lung cancer and gRNA for inhibiting ACBD3 gene expression, and belongs to the field of bioengineering.199 binding proteins of ACBD3 are obtained through co-immunoprecipitation and mass spectrum identification, new biological functions of ACBD3 are excavated through GO analysis and KEGG pathway analysis of the binding proteins of ACBD3, and the application of the ACBD3 inhibitor in preparation of the medicine for treating lung cancer is developed. The ACBD3 is used for regulating and controlling a KEGG pathway enrichment map of a differential gene, and the ACBD3 is found to participate in the occurrence and development of cancers; the ACBD3 is successfully knocked out by designing gRNA, and tests prove that the multiple effects of slowing down A549 lung cancer cell proliferation, inhibiting lung cancer cell migration, inhibiting A549 lung cancer cell invasion, retarding A549 cell cycle G1 phase and reducing tumorigenicity can be achieved by knocking out the ACBD3.
Owner:FIRST PEOPLES HOSPITAL OF YUNNAN PROVINCE
Pheromone binding protein derived peptide capable of effectively monitoring sex pheromones of fall webworms and biosensor
The invention discloses a pheromone binding protein derived peptide capable of effectively monitoring sex pheromones of fall webworms and a biosensor, and belongs to the field of biosensors. At present, methods such as sample plot survey and sex traps commonly used in fall webworm monitoring have the problems of poor timeliness, high labor cost, insufficient data continuity and the like. In order to solve the problem, the pheromone binding protein-derived peptide provided by the invention has an amino acid sequence as shown in SEQ ID NO: 2, the biosensor comprises a substrate and an interdigital electrode, a single-walled carbon nanotube is attached to the electrode, and the electrode is also connected with the pheromone binding protein-derived peptide. The sensor can specifically detect sex pheromones of fall webworms, has no response to 17 plant volatile matters, and can detect sex pheromones released by as low as five live female fall webworms under laboratory conditions. The method has application potential in the fields of early pest monitoring, prevention and control efficiency improvement, ecological safety guarantee and the like.
Owner:NORTHEAST FORESTRY UNIV
Nanoparticle compositions and methods for biological measurements
This disclosure provides nanoparticle compositions, and use thereof for isolating and measuring proteins, protein degrader action, and cells. The disclosed nanoparticles can be identified by barcodes that reveal the identity of and post translational modifications to the bound protein using image processing techniques described herein.
Owner:INCYTO DISCOVERY LLC
Albumin binding proteins and methods of use
PCT designated stageWO2025217488A1Serum albuminImmunoglobulins against animals/humansAlbuminCell biology
Owner:PARAGON THERAPEUTICS INC
Variant RNA-guided cas12f4 nucleases and DNA binding proteins
PendingUS20250327095A1Polypeptide with localisation/targeting motifAntibody mimetics/scaffoldsNucleaseEx vivo
Provided are variant Cas12f4 polypeptides, fusion proteins containing variant Cas12f4 polypeptides, nucleic acids encoding variant Cas12f4 polypeptides and fusion proteins, compositions and methods related to those variant Cas12f4 polypeptides and fusion proteins, and modified host cells comprising the variant Cas12f4 polypeptides and / or encoding nucleic acids. The variant Cas12f4 polypeptides disclosed herein exhibit improved functionality, stability, and / or other desirable properties and may be used in combination with guide Cas12f4 RNAs that can be used in a variety of applications ex vivo, in vitro, and in vivo.
Owner:INARI AGRICULTURE TECHNOLOGY INC
Antigen-binding proteins that activate the leptin receptor
The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
Owner:REGENERON PHARMACEUTICALS INC
Universal HLA antigen presentation prediction method and system based on protein language model and multi-modal neural network
The invention discloses a universal HLA antigen presentation prediction method based on a protein language model and a multi-modal neural network, which comprises the following steps: firstly, extracting verified HLA binding peptide fragment sequences from an immune epitope database, generating equivalent non-epitope peptide fragment sequences in combination with a protein database, and constructing an HLA-I class and HLA-II class balanced data set; then, extracting sequence embedding characteristics and contact graph structure information of the peptide fragment sequence by utilizing a protein language model; the method comprises the following steps: processing a protein map constructed by a contact map through a map neural network to obtain global structure features, and meanwhile, carrying out regional convolution and residual convolution processing on sequence embedding by adopting a one-dimensional convolutional neural network (1DCNN) to extract local context sequence features; the method effectively fuses sequence semantics and space structure information, improves the accuracy and generalization ability of HLA antigen presentation prediction, and is suitable for immune recognition modeling tasks under various HLA subtypes.
Owner:WUHAN HUADA ZHIYAN TECHNOLOGY CO LTD +1